Prothena (PRTA) announced partner Roche (RHHBY) will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson’s disease. “This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions from both PADOVA and the Phase II PASADENA study,” the company said in a statement. The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson’s disease, are ongoing, it added. Shares of Prothena are up 13%, or 67c, to $5.75 in premarket trading.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena’s Prasinezumab Advances to Phase III for Parkinson’s
- Altria, Prime Medicine, US Steel, DLocal, Prothena: Trending by Analysts
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Prothena downgraded to Underperform at BofA after birtamimab fails in clinic
- Prothena downgraded to Underperform from Neutral at BofA